- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Myosin Therapeutics Invited to Present at Biocom California's Global Partnering & Investor Conference
The biotechnology company will showcase its oncology pipeline and discuss clinical milestones at the upcoming industry event.
Jan. 29, 2026 at 5:15pm
Got story updates? Submit your updates here. ›
Myosin Therapeutics, a biotechnology company based in Jupiter, Florida, has been selected to present at Biocom California's Global Partnering & Investor Conference taking place from February 24-26, 2026. The company's CEO, Courtney Miller, PhD, and Chief Medical Officer, Karen Smith, MD, PhD, MBA, LLM, will discuss Myosin's progress and future direction, with a focus on the company's lead program MT-125 for glioblastoma (GBM).
Why it matters
The Biocom California conference is a key industry event that brings together investors, business development leaders, and emerging biotechs to catalyze collaboration and dealmaking. Myosin's presentation and participation in the conference will enable the company to have important conversations that can help advance its clinical development and operational scaling around GBM and other aggressive cancers.
The details
Myosin Therapeutics is developing first-in-class therapies for oncology and CNS disorders by targeting molecular nanomotor proteins. The company's lead program, MT-125, is in Phase 1/2 clinical trials for glioblastoma and has received FDA Orphan Drug Designation and Fast Track Designation. Myosin is also planning to initiate clinical trials for MT-125 in acute myeloid leukemia (AML) in 2026. The company's science is supported by peer-reviewed publications, non-dilutive federal funding, and an experienced executive team.
- Biocom California's Global Partnering & Investor Conference will take place from February 24-26, 2026.
- Myosin Therapeutics is on track to report the STAR-GBM safety readout for MT-125 this year, which will position the company to immediately begin the Phase 2 dose expansion portion of the trial.
The players
Myosin Therapeutics
A biotechnology company based in Jupiter, Florida, developing first-in-class therapies for oncology and CNS disorders by targeting molecular nanomotor proteins.
Courtney Miller
Chief Executive Officer of Myosin Therapeutics.
Karen Smith
Chief Medical Officer of Myosin Therapeutics.
What they’re saying
“Our focus is on oncology, advancing MT-125 in orphan cancers to build a durable franchise in cancer cell mechanics.”
— Courtney Miller, Chief Executive Officer
“As CMO, I look forward to discussing our near-term clinical milestones and site readiness with prospective collaborators. Our goal is to align on practical execution, study design, endpoints, and pathways that matter most to patients and physicians.”
— Karen Smith, Chief Medical Officer
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
Myosin Therapeutics' presentation at the Biocom California conference will be an important opportunity for the company to showcase its oncology pipeline and discuss its clinical milestones with potential investors and strategic partners, as it looks to advance its lead program MT-125 for glioblastoma and expand into other aggressive cancer indications.
